⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Official Title: Primary Prevention of Anthracycline-Induced Cardiotoxicity With L-Carnitine in Patients With Breast Cancer (PPACC)-Pilot Study

Study ID: NCT00247975

Conditions

Heart Failure

Interventions

L-carnitine

Study Description

Brief Summary: Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines". Anthracyclines can damage the heart resulting in heart failure and even death. Clinicians and researchers are continually seeking methods that will reduce the toxic effects of anthracycline treatment. L-carnitine is a substance that is produced naturally in the body and is required for normal heart function. Animal studies have suggested that L-carnitine protects the heart from the effects of anthracyclines, however this has not been verified in humans. This study will assess the potential role of L-carnitine in the prevention of anthracycline induced heart damage. The investigators will enroll 144 patients into this study. Patients will be randomly assigned to L-carnitine therapy or to standard care (no L-carnitine therapy). Patients in the L-carnitine group will receive oral and intravenous L-carnitine prior to and after their anthracycline therapy. Patients will undergo regular follow up and testing to assess heart function. The investigators believe that patients treated with L-carnitine will benefit and have fewer complications associated with anthracycline treatment.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Contact Details

Name: Benjamin JW Chow, MD, FRCPC

Affiliation: Ottawa Heart Institute Research Corporation

Role: PRINCIPAL_INVESTIGATOR

Name: Rob S Beanlands, MD, FRCPC

Affiliation: Ottawa Heart Institute Research Corporation

Role: STUDY_CHAIR

Name: Haissam Haddad, MD, FRCPC

Affiliation: Ottawa Heart Institute Research Corporation

Role: STUDY_CHAIR

Name: George Wells, M.Sc., PhD

Affiliation: Ottawa Heart Institute Research Corporation

Role: STUDY_CHAIR

Name: Susan Dent, MD, FRCPC

Affiliation: Ottawa Regional Cancer Centre

Role: STUDY_CHAIR

Name: Sean Hopkins, B.Sc, RPEBC

Affiliation: Ottawa Regional Cancer Centre

Role: STUDY_CHAIR

Name: Michele A Turek, MD, FRCPC

Affiliation: Ottawa Hospital

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: